


ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

April 20, 2022



cdc.gov/coronavirus

Daily Trends in Number of COVID-19 Cases, United States


January 23, 2020 – April 17, 2022




CDC COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#trends_dailycases Accessed April 19, 2022

Daily Trends in Number of COVID-19 Deaths, United States

January 23, 2020 – April 11, 2022



Age-Adjusted Rates of COVID-19 Cases & Deaths by Vaccination Status and Receipt of Booster Dose,*



Unvaccinated people aged 12 years and older had:

3.1X
Risk of Testing Positive for COVID-19

AND

20X
Risk of Dying from COVID-19

in February, and

2.0X
Risk of Testing Positive for COVID-19

in March, compared to people vaccinated with a primary series and a booster dose.

*This includes people who received booster doses and people who received additional doses.

** Data from September 19, 2021 – March 19, 2022 (24 U.S. jurisdictions)

+ Data from September 19, 2021 – February 26, 2022 (23 U.S. jurisdictions)

CDC COVID Data Tracker. <https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status> Accessed April 19, 2022

FDA updates

FDA authorizes second booster dose of two COVID-19 vaccines

- On March 29, 2022: FDA authorized a second booster dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine for older people and immunocompromised individuals
 - A second booster dose of the Pfizer-BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
 - A second booster dose of the Pfizer-BioNTech COVID-19 vaccine may be administered to individuals 12 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.
 - A second booster dose of the Moderna COVID-19 Vaccine may be administered to individuals 18 years of age and older with certain kinds of immunocompromise at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine

CDC update

CDC issues Emergency Use Instructions for mRNA COVID-19 vaccines

- On March 29, 2021, CDC issued Emergency Use Instructions (EUI) for the use of both mRNA COVID-19 vaccines stating that people ages 18–49 who received Janssen COVID-19 vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose
- The EUI allows CDC to permit emergency use of FDA-approved medical products
 - EUI are provided as fact sheets for healthcare providers and recipients
 - Include information about such products' approved, licensed, or cleared conditions of use under circumstances that go beyond the scope of the approved labeling

Emergency Use Authorization and Emergency Use Instructions

EUA¹

- People ages 50 years and older
- People ages 12 years and older who are moderately or severely immunocompromised

EUI²

- People ages 18 years and older who received Janssen as both primary and booster dose

¹<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>


²<https://www.cdc.gov/vaccines/covid-19/eui/index.html>

Summary of Recommendations by Primary Series Product and Age


People who are not moderate to severely immunocompromised

 **Everyone** in the age group **SHOULD** receive the dose  **Some people** in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5–11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



People ages 18 years and older who received 2 Janssen doses

People ages 50 years and older

COVID-19 vaccine Work Group activities

February-April 2022

Reviewed data around:

- Vaccine effectiveness data for COVID-19 vaccines in children ages 5-11 years
- COVID-19 vaccine safety updates in children ages 5-11 years
- Survey data for intent to receive COVID-19 vaccines among children
- Safety and efficacy of Novavax COVID-19 vaccine
- Overview of infection-induced and hybrid immunity to COVID-19
- Vaccine effectiveness for booster doses
- Safety data for COVID-19 vaccine booster doses
- Policy discussions around booster doses
- Framework, data need for future doses of COVID-19 vaccines

Agenda: Wednesday April 20, 2022

- **Updates on vaccine effectiveness of COVID-19 booster dose**

Dr. Link-Gelles (CDC)

- **Updates on safety of COVID-19 booster dose**

Dr. Klein (KPNC)

Dr. Shimabukuro (CDC)

- **VaST assessment**

Dr. Talbot (ACIP, VaST chair)

Break

- **Updates to the EtR Framework: COVID-19 vaccine booster doses in adults ages ≥ 50 years and immunocompromised individuals**

Dr. Oliver (CDC)

- **CDC guidance for second COVID-19 booster dose**

Dr. Hall (CDC)

Discussion

- **PUBLIC COMMENT**

Agenda (continued): Wednesday April 20, 2022

Break

- **Summary of FDA advisory committee meeting on future COVID-19 vaccine doses** Dr. Fink (FDA)
- **Framework for Future COVID-19 doses and next steps** Dr. Oliver (CDC)

Discussion

Work Group members

ACIP members

- Matthew Daley (chair)
- Beth Bell
- Grace Lee
- Keipp Talbot
- Oliver Brooks

Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

CDC Lead

- Sara Oliver

Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary),
Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary),
Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary),
Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Christine Hahn (primary),
Paul Cieslak (alternate)
- IDSA: Jeff Duchin (primary),
Carol Baker (alternate)

Liaisons, cont’d


- NACCHO: Matt Zahn (primary),
Jeff Duchin (alternate)
- NACI: Matthew Tunis
- NFID: Bill Schaffner (primary),
Marla Dalton (alternate)
- NMA: Patricia Whitley-Williams
- SHEA: Marci Drees

Consultants

- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
- Jose Romero
- Hank Bernstein

CDC participants

- Sarah Mbaeyi
- Evelyn Twentyman
- Tara Anderson
- Mary Chamberland
- Amanda Cohn
- Jack Gersten
- Monica Godfrey
- Stephen Hadler
- Danielle Moulia
- Megan Wallace
- Susan Goldstein
- Jefferson Jones
- Edwin Shanley
- Karen Broder
- Kathleen Dooling
- Sam Graitcer
- Rita Helfand
- Terri Hyde
- Cynthia Jorgensen
- Andrew Kroger
- Ruth Link-Gelles
- Jessica MacNeil
- Lauri Markowitz
- Valerie Morelli
- Kristin Nordland
- Tamara Pilishvili
- Heather Scobie
- Tom Shimabukuro
- Natalie Thornburg
- Melinda Wharton
- JoEllen Wolicki
- Yon Yu



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

